Dermatomyositis Flare After a COVID-19 Infection Successfully Treated with Rituximab: A Case Report and Literature Review

Dermatomyositis Flare After a COVID-19 Infection Successfully Treated with Rituximab: A Case Report and Literature Review

Blog Article

Ahmed Mohammed Albakri, Ahmed Hussein Subki, Abdurahman Albeity, Hussein Halabi Department of Medicine, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi ArabiaCorrespondence: Ahmed Hussein Subki; Hussein Halabi, Department of Internal Medicine, King Faisal Specialist Hospital and Research Center, POBox: 43129, Jeddah, 21561, Saudi Arabia, Tel +966566724288, Email [email protected]; mfasel@gmail.

comIntroduction: Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, Lounge Socks there has been a sudden surge in the incidence of several immune-mediated diseases, including dermatomyositis.The reported cases of COVID-19-related dermatomyositis are heterogeneous in their clinical presentation and implemented therapies.Case Study: We report a 23-year-old female patient diagnosed with a 3-year history of dermatomyositis.

She has been well-controlled on maintenance therapy.However, 6 weeks after a mild COVID-19 infection, she developed a dermatomyositis flare.She improved only after aggressive treatment Santa Decoration with pulse steroids, intravenous immunoglobulin, and rituximab.

Conclusion: Exacerbation of dermatomyositis can be encountered following a COVID-19 infection, even if the infection is mild.Aggressive therapy should be considered in such cases.The prognosis, however, is generally favorable.

Keywords: COVID-19 infection, dermatomyositis, Rituximab.